Prothena Co. plc (NASDAQ:PRTA) CFO Tran Nguyen sells 7,320 shares
Prothena Co. plc (NASDAQ:PRTA – Get Rating) Chief Financial Officer Tran Nguyen sold 7,320 shares of the company in a trade dated Friday July 22. The stock was sold at an average price of $32.55, for a total transaction of $238,266.00. Following the completion of the transaction, the CFO now owns 3,200 shares of the company, valued at $104,160. The transaction was disclosed in a document filed with the SEC, accessible via this hyperlink.
Tran Nguyen has also recently made the following trade(s):
- On Wednesday, July 20, Tran Nguyen sold 42,120 Prothena shares. The shares were sold at an average price of $32.49, for a total transaction of $1,368,478.80.
Prothena is trading down 5.6%
Shares of PRTA were down $1.85 at midday Friday, hitting $31.01. The stock recorded a trading volume of 593,743 shares, compared to an average volume of 424,547 shares. Prothena Co. plc has a fifty-two week low of $21.06 and a fifty-two week high of $79.75. The company has a 50-day simple moving average of $27.47 and a two-hundred-day simple moving average of $32.33. The company has a market capitalization of $1.45 billion, a P/E ratio of 25.42 and a beta of 1.30.
Prothena (NASDAQ:PRTA – Get Rating) last released its quarterly results on Thursday, May 5. The biotech company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.07. The company posted revenue of $1.15 million in the quarter, versus $0.23 million expected by analysts. Prothena had a net margin of 33.45% and a return on equity of 16.02%. On average, analysts expect Prothena Co. plc to post earnings per share of -2.53 for the current financial year.
Institutional investors weigh in on Prothena
A d Invest daily
27 US cities where stocks earn 26% a year
What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%! When you start getting paid 26% on your money, your financial troubles tend to evaporate.
A number of institutional investors have recently bought and sold shares of PRTA. Allegheny Financial Group LTD bought a new position in Prothena shares in the fourth quarter worth approximately $49,000. Spire Wealth Management increased its holdings in Prothena by 938.8% during the 4th quarter. Spire Wealth Management now owns 1,070 shares of the biotech company worth $53,000 after buying 967 additional shares in the last quarter. Lazard Asset Management LLC increased its stake in Prothena shares by 61.1% in the 1st quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotech company valued at $63,000 after acquiring 657 additional shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Prothena shares by 237.8% in Q4. Nisa Investment Advisors LLC now owns 3,479 shares of the biotech company valued at $119,000 after acquiring 2,449 additional shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in Prothena shares in Q1 worth approximately $141,000. Institutional investors and hedge funds own 92.64% of the company’s shares.
A Wall Street analyst gives his opinion
Several stock analysts have commented on PRTA shares. StockNews.com took over coverage of Prothena shares in a Thursday, March 31 research note. They have set a “holding” rating on the stock. JMP Securities cut its price target on Prothena shares from $77.00 to $50.00 and set a “market outperformance” rating for the company in a Wednesday, May 25 research report. One equity research analyst gave the stock a hold rating and five gave the company’s stock a buy rating. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.33.
Prothena Company Profile
(Get a rating)
Prothena Corporation plc, a late-stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is involved in the development of birtamimab, an investigational humanized antibody that is in a phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in a phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 which has completed the Phase I clinical trial for the treatment of transthyretin amyloidosis; and PRX005, which is in a phase I clinical trial for the treatment of Alzheimer’s disease.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Should you invest $1,000 in Prothena right now?
Before you consider Prothena, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Prothena wasn’t on the list.
Although Prothena currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here